Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03140722 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents
A Phase 2 study, sponsored by Akebia Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03140722 is a Phase 2 study that was terminated before completion, run by Akebia Therapeutics. The registered enrollment target is 2 participants.
The verdict
NCT03140722, a Phase 2 study, was terminated before completion, sponsored by Akebia Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, open-label study to evaluate vadadustat versus epoetin alfa for the treatment of anemia in subjects with Dialysis-dependent Chronic Kidney Disease (DD-CKD) who are hyporesponsive to erythropoiesis stimulating agents (ESAs.)
Interventions
- DRUG epoetin alfa
- DRUG vadadustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-05-02 |
| Est. Completion | 2018-03-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03140722
The ClinicalTrials.gov registry entry for NCT03140722 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akebia Therapeutics, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which epoetin alfa is the first listed.
NCT03140722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03140722 about?
NCT03140722 is a clinical study titled "Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents". This is a Phase 2, randomized, open-label study to evaluate vadadustat versus epoetin alfa for the treatment of anemia in subjects with Dialysis-dependent Chronic Kidney Disease (DD-CKD) who are hyporesponsive to erythropoiesis stimulating agents (ESAs.)
What is the current status of trial NCT03140722?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2017-05-02. Estimated completion is 2018-03-21.
What interventions are being tested in trial NCT03140722?
The interventions under investigation include: epoetin alfa (DRUG), vadadustat (DRUG).
Who is sponsoring clinical trial NCT03140722?
This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.